Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press18610.17650/2220-3478-2016-6-4-13-17ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORGAN SAVING TREATMENT OF RECTAL CANCERОРГАНОСОХРАНЯЮЩЕЕ ЛЕЧЕНИЕ РАКА ПРЯМОЙ КИШКИRasulovA. O.РасуловА. О.
Russian Federation

Department of Colorectal Cancer

Отделение онкопроктологии

MamedliZ. Z.МамедлиЗ. З.
Russian Federation

23 Kashirskoe Shosse,Moscow115478,Russia; 

Контакты: Заман Заурович Мамедли - ФГБУ РОНЦ им. Н.Н. Блохина Минздрава России, 115478 Москва, Каширское шоссе, 23

z.z.mamedli@gmail.comKuz’michevD. V.КузьмичевД. В.
Russian Federation

Department of Colorectal Cancer

Отделение онкопроктологии

KhudoerovD. H.ХудоеровД. Х.
Russian Federation

Отделение онкопроктологии

KozlovN. A.КозловН. А.
Russian Federation

Department of Pathomorphlogy

Отделение патоморфологии

SuraevaYu. E.СураеваЮ. Э.
Russian Federation

Department of Diagnostic Imaging

Отделение лучевой диагностики

BalyasnikovaS. S.БалясниковаС. С.
United Kingdom

Department of Diagnostic Imaging

Отделение лучевой диагностики

N.N. Blokhin Russian Cancer Research CenterРоссийский онкологический научный центр им. Н.Н. Блохина Минздрава РоссииRoyal Mardsen Hospital040120176413170401201704012017Copyright ©; 2017, Rasulov A.O., Mamedli Z.Z., Kuz’michev D.V., Khudoerov D.H., Kozlov N.A., Suraeva Y.E., Balyasnikova S.S.Copyright ©; 2017, Расулов А.О., Мамедли З.З., Кузьмичев Д.В., Худоеров Д.Х., Козлов Н.А., Сураева Ю.Э., Балясникова С.С.2017Rasulov A.O., Mamedli Z.Z., Kuz’michev D.V., Khudoerov D.H., Kozlov N.A., Suraeva Y.E., Balyasnikova S.S.Расулов А.О., Мамедли З.З., Кузьмичев Д.В., Худоеров Д.Х., Козлов Н.А., Сураева Ю.Э., Балясникова С.С.https://creativecommons.org/licenses/by/4.0https://onco-surgery.info/jour/article/view/186

Objective: to evaluate the results of “watch and wait” approach for rectal cancer patients with complete clinical response after neoadjuvant chemoradiotherapy (CRT) followed by consolidation chemotherapy.

Materials and methods. Between 2013 and 2016, 130 patients who were diagnosed with stage T2N0–1M0–T3(CRM+)–4N0–2M0 middle and low rectal cancer were treated by CRT (single dose 2 Gy to a total dose 50–54 Gy with concominant capecitabine 850 mg/m2 /day of radiotherapy) with consolidation chemotherapy (CapOx) (capecitabine 2000 mg/m2 14 days and oxaliplatin 130 mg/m2 intravenous once in 3 weeks).

Results. 21 patient showed complete clinical response. During the time of observation (median 14.6 month) all patients alive without signs of recurrence and progression.

Conclusion. Preliminary results showed that organ saving treatment for rectal cancer patients with a complete clinical response is oncologically safe when followed by strict selection criteria and active follow-up, including endoscopy and magnetic resonance imagin. Future investigation is needed to justify this statement. Probability of complete response is higher for early stages of rectal cancer. 

rectal cancerneoadjuvant chemoradiotherapyconsolidation chemotherapycomplete clinical responsetransanal endoscopic microsurgeryрак прямой кишкинеоадъювантная химиолучевая терапияконсолидирующая химиотерапияполный клинический ответтрансанальная эндоскопическая микрохирургия1. McCarthy K., Pearson K., Fulton R., Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012;12:CD008368. DOI: 10.1002/14651858.CD008368.pub2.McCarthy K., Pearson K., Fulton R., Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev 2012;12:CD008368. DOI: 10.1002/14651858.CD008368.pub2.2. Gerard A., Buyse M., Nordlinger B. et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomised study of the European Organisation for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208(5):606–14.Gerard A., Buyse M., Nordlinger B. et al. Preoperative radiotherapy as adjuvant treatment in rectal cancer: final results of a randomised study of the European Organisation for Research and Treatment of Cancer (EORTC). Ann Surg 1988;208(5):606–14.3. Minsky B.D., Cohen A.M., Kemeny N. et al. Efficacy of preoperative 5-FU, high dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 1993;71(1):3486–92.Minsky B.D., Cohen A.M., Kemeny N. et al. Efficacy of preoperative 5-FU, high dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. Cancer 1993;71(1):3486–92.4. Chen E.T., Mohiuddin M., Brodovsky H. et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994;30:169–75.Chen E.T., Mohiuddin M., Brodovsky H. et al. Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. Int J Radiat Oncol Biol Phys 1994;30:169–75.5. Renehan A.G., Malcomson L., Emsley R. et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17(2):174–83. DOI: 10.1016/S1470-2045(15)00467-2.Renehan A.G., Malcomson L., Emsley R. et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 2016;17(2):174–83. DOI: 10.1016/S1470-2045(15)00467-2.6. Paun B.C., Cassie S., MacLean A.R. et al. Postoperative complications following surgery for rectal cancer. Ann Surg 2010;251(5):807–18. DOI: 10.1097/SLA.0b013e3181dae4ed.Paun B.C., Cassie S., MacLean A.R. et al. Postoperative complications following surgery for rectal cancer. Ann Surg 2010;251(5):807–18. DOI: 10.1097/SLA.0b013e3181dae4ed.7. Ferrari L., Fichera A., Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep 2015;3(4):277–88. DOI: 10.1093/gastro/gov039.Ferrari L., Fichera A., Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer. Gastroenterol Rep 2015;3(4):277–88. DOI: 10.1093/gastro/gov039.8. Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7.Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7.9. Patel U.B., Blomgvist L.K., Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor responsethe MERCURY experience. AJR Am J Roentgenol 2012;199(4):W486–95.Patel U.B., Blomgvist L.K., Taylor F. et al. MRI after treatment of locally advanced rectal cancer: how to report tumor responsethe MERCURY experience. AJR Am J Roentgenol 2012;199(4):W486–95.10. Rutten H., Glynne-Jones D.S.-M., Rullier E. et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 2006;(Suppl; abstr 3528): 24(153s).Rutten H., Glynne-Jones D.S.-M., Rullier E. et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. J Clin Oncol 2006;(Suppl; abstr 3528): 24(153s).11. Maas M., Beets-Tan R.G., Lambregts D.M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Clin Oncol 2011;29(35):4633–40.Maas M., Beets-Tan R.G., Lambregts D.M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Clin Oncol 2011;29(35):4633–40.12. Habr-Gama A., Perez R.O., Proscurshim I. et al. Patterns of failure and survival for non-operative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006;10:1319–29.Habr-Gama A., Perez R.O., Proscurshim I. et al. Patterns of failure and survival for non-operative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006;10:1319–29.13. Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7.Habr-Gama A., Perez R.O., Nadalin W. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7.14. Habr-Gama A., Gama-Rodrigues J., Sao Juliano G.P. et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88(4):822–8. DOI: 10.1016/j.ijrobp.2013.12.012.Habr-Gama A., Gama-Rodrigues J., Sao Juliano G.P. et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88(4):822–8. DOI: 10.1016/j.ijrobp.2013.12.012.15. Patel U.B., Taylor F., Blomqvist L. et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29(28):3753–60. DOI: 10.1200/JCO.2011.34.9068.Patel U.B., Taylor F., Blomqvist L. et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011;29(28):3753–60. DOI: 10.1200/JCO.2011.34.9068.16. Dresen R.C., Beets G.L., Rutten H.J. et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumour confined to the rectal wall? Radiology 2009;252(1):71–80. DOI: 10.1148/radiol.2521081200.Dresen R.C., Beets G.L., Rutten H.J. et al. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumour confined to the rectal wall? Radiology 2009;252(1):71–80. DOI: 10.1148/radiol.2521081200.17. Smith F.M., Waldron D., Winter D.C. Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg 2010; 97(12):1752–64. DOI: 10.1002/bjs.7251.Smith F.M., Waldron D., Winter D.C. Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg 2010; 97(12):1752–64. DOI: 10.1002/bjs.7251.18. Balyasnikova S., Bhoday J., Siddiqui M. et al. Is there any added value of DWI, mrVolumetric regression and mrRECIST analyses against mrTRG in finding patients with maintained complete response for deferral of surgery trial approach? ESCP, 2016;(Abstr 0711).Balyasnikova S., Bhoday J., Siddiqui M. et al. Is there any added value of DWI, mrVolumetric regression and mrRECIST analyses against mrTRG in finding patients with maintained complete response for deferral of surgery trial approach? ESCP, 2016;(Abstr 0711).19. Smith F.M., Brown G., Heald R.J. et al. O’Neill B.D., Brown G et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007;8(7):625–33.Smith F.M., Brown G., Heald R.J. et al. O’Neill B.D., Brown G et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007;8(7):625–33.20. Maas M., Beets-Tan R.G., Lambregts D.M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Clin Oncol 2011;29(35):4633–40.Maas M., Beets-Tan R.G., Lambregts D.M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. Clin Oncol 2011;29(35):4633–40.21. Maas M., Nelemans P.J., Valentini V. et al. Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of 3105 patients. Lancet Oncol 2011;11:835–44.Maas M., Nelemans P.J., Valentini V. et al. Long-term outcome in patients with a pathologic complete response after chemoradiation for rectal cancer: a pooled analysis of 3105 patients. Lancet Oncol 2011;11:835–44.22. Gao Y.H., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol 2014;90(2):158–64.Gao Y.H., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol 2014;90(2):158–64.23. Verseveld M., de Graaf E.J., Verhoef C. et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015;102(7):853–60.Verseveld M., de Graaf E.J., Verhoef C. et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015;102(7):853–60.24. Garcia-Aguilar J., Renfro L.A., Chow O.S. et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multiinstitutional, phase 2 trial. Lancet Oncol 2015;16(15):1537–46.Garcia-Aguilar J., Renfro L.A., Chow O.S. et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multiinstitutional, phase 2 trial. Lancet Oncol 2015;16(15):1537–46.25. Lambregts D.M., Cappendijk V.C., Maas M. et al. Value of MRI and diffusionweighted MRI for the diagnosis of locally recurrent cancer. Eur Radiol 2011;21:1250–8.Lambregts D.M., Cappendijk V.C., Maas M. et al. Value of MRI and diffusionweighted MRI for the diagnosis of locally recurrent cancer. Eur Radiol 2011;21:1250–8.